Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 5/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | DRD4 | P21917 | 6/20 | 0.37 |
| ▸ | DRD2 | P14416 | 4/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23044895 | 0.81 | FGFR1 (0.39) | LMNAMAPTDRD4MAPK10TSHR | |
| SCHEMBL29214324 | 0.80 | ALDH1A1 (0.38) | HTR4LMNAALDH1A1HTR7MAPT | |
| SCHEMBL23044993 | 0.80 | ADRB1 (0.43) | MAPTNPC1MEN1KMT2ACHRM4 | |
| SCHEMBL23044919 | 0.79 | HTR4 (0.42) | HTR4LMNAALDH1A1HTR7MAPT | |
| SCHEMBL23044885 | 0.79 | NPC1 (0.43) | LMNAALDH1A1MAPTNPC1MEN1 | |
| SCHEMBL23044915 | 0.76 | MAPT (0.45) | LMNAALDH1A1MAPTMEN1HTT | |
| SCHEMBL23044874 | 0.72 | HTR4 (0.44) | HTR4ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL23044917 | 0.72 | KDM4E (0.48) | HTR4ALDH1A1HTR7MAPTDRD4 | |
| SCHEMBL23060231 | 0.68 | CFTR (0.34) | ALDH1A1MAPTTSHR | |
| SCHEMBL19328837 | 0.68 | MAPT (0.53) | LMNAALDH1A1MAPTNPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220298143-A1 | Pyrazole Derivatives for FGFR Inhibitor and Preparation Method Thereof | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2022-09-22 | — | — | US | disclosed |
| CN-114728910-A | Pyrazole derivatives for FGFR inhibitor and preparation method thereof | 上海奕拓医药科技有限责任公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-4023639-A1 | PYRAZOLE DERIVATIVE FOR FGFR INHIBITOR AND PREPARATION METHOD THEREFOR | Etern Biopharma (Shanghai) Co., Ltd. (CN) | 2022-07-06 | — | — | EP | disclosed |
| WO-2021037219-A1 | PYRAZOLE DERIVATIVE FOR FGFR INHIBITOR AND PREPARATION METHOD THEREFOR | 上海奕拓医药科技有限责任公司 | 2021-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298143-A1 | Pyrazole Derivatives for FGFR Inhibitor and Preparation Method Thereof | FGFR1, FGFR2, FGFR3 | HTR4 4679/4885LMNA 4643/4885ALDH1A1 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.